Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omegaven with EOX Chemotherapy in Advanced Oesophagogastric Cancer
NCT01870791Phase 2Terminated
- Sponsor
- University Hospitals of Leicester NHS Trust
- Start
- May 2012
- Primary completion
- Dec 2015
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eicosapentaenoic acid + docosahexaenoic acid in esophageal carcinoma and Gastric carcinoma (GC), sponsored by University Hospitals of Leicester NHS Trust. Primary endpoint: Overall Survival at 12 months. Started May 2012; status: terminated.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
esophageal carcinomaGastric carcinoma (GC)
Beyond the preview
Go deeper on NCT01870791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01870791.